Six-dog study highlights challenges of M. abscessus infection

A new retrospective study in the Journal of Small Animal Practice describes six dogs with confirmed Mycobacterium abscessus infection, a rare but clinically important non-tuberculous mycobacterial disease in canine patients. The cases presented with either respiratory disease or cutaneous lesions, and diagnosis relied on mycobacterial culture plus PCR-based identification, according to the study abstract. Treatment centered on clarithromycin-based multidrug therapy, but outcomes varied: some dogs recovered, while others relapsed or were euthanized. The report adds a small but useful case series to a literature base where rapidly growing mycobacteria in dogs are considered uncommon, diagnostically challenging, and often associated with chronic, nonhealing lesions or pulmonary disease. (merckvetmanual.com)

Why it matters: For veterinary professionals, the main takeaway is that M. abscessus should stay on the differential list for dogs with persistent nodular or draining skin disease, granulomatous inflammation, or respiratory signs that don’t fit more routine bacterial infections. The organism is part of the M. chelonae-abscessus group, which is known for limited antimicrobial susceptibility and prolonged treatment courses; current veterinary guidance generally recommends a macrolide such as clarithromycin or azithromycin combined with additional agents, often for months, with relapse remaining a real risk. The study’s use of culture and PCR also reinforces the need for species-level identification rather than empiric treatment alone, especially given antimicrobial stewardship concerns and the potential zoonotic relevance of some non-tuberculous mycobacteria for immunocompromised pet parents. (bsavalibrary.com)

What to watch: Watch for the full paper’s publication details and any follow-on commentary clarifying susceptibility testing, infection-control recommendations, and whether certain clinical presentations or treatment combinations were linked with better outcomes. (ovid.com)